![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HMCN1 |
Gene summary for HMCN1 |
![]() |
Gene information | Species | Human | Gene symbol | HMCN1 | Gene ID | 83872 |
Gene name | hemicentin 1 | |
Gene Alias | ARMD1 | |
Cytomap | 1q25.3-q31.1 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q96RW7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83872 | HMCN1 | HCC1_Meng | Human | Liver | HCC | 1.67e-34 | 1.05e-01 | 0.0246 |
83872 | HMCN1 | S014 | Human | Liver | HCC | 2.57e-06 | 1.11e+00 | 0.2254 |
83872 | HMCN1 | S015 | Human | Liver | HCC | 2.47e-02 | 6.66e-01 | 0.2375 |
83872 | HMCN1 | S016 | Human | Liver | HCC | 2.93e-26 | 1.32e+00 | 0.2243 |
83872 | HMCN1 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 1.73e-02 | 7.16e-01 | -0.1406 |
83872 | HMCN1 | RNA-P23T2-P23T2-2 | Human | Lung | MIAC | 2.54e-09 | 1.38e+00 | -0.028 |
83872 | HMCN1 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 1.88e-05 | 8.05e-01 | -0.0961 |
83872 | HMCN1 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 2.30e-08 | 9.42e-01 | -0.0876 |
83872 | HMCN1 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 4.12e-04 | 6.55e-01 | -0.0822 |
83872 | HMCN1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 5.57e-09 | 8.81e-01 | -0.0809 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HMCN1 | SNV | Missense_Mutation | novel | c.1103N>T | p.Ser368Leu | p.S368L | Q96RW7 | protein_coding | deleterious(0) | benign(0.057) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
HMCN1 | SNV | Missense_Mutation | novel | c.7393N>A | p.Glu2465Lys | p.E2465K | Q96RW7 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
HMCN1 | SNV | Missense_Mutation | c.1256C>T | p.Ser419Leu | p.S419L | Q96RW7 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
HMCN1 | SNV | Missense_Mutation | rs137853916 | c.6917G>A | p.Arg2306Gln | p.R2306Q | Q96RW7 | protein_coding | tolerated(1) | possibly_damaging(0.653) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
HMCN1 | SNV | Missense_Mutation | novel | c.5353N>G | p.Leu1785Val | p.L1785V | Q96RW7 | protein_coding | tolerated(0.28) | probably_damaging(0.994) | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
HMCN1 | SNV | Missense_Mutation | rs868851615 | c.9590C>T | p.Ser3197Leu | p.S3197L | Q96RW7 | protein_coding | deleterious(0.01) | benign(0.243) | TCGA-A7-A2KD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
HMCN1 | SNV | Missense_Mutation | rs766042341 | c.12320C>T | p.Pro4107Leu | p.P4107L | Q96RW7 | protein_coding | tolerated(0.19) | benign(0.342) | TCGA-A7-A2KD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
HMCN1 | SNV | Missense_Mutation | c.1765N>A | p.Tyr589Asn | p.Y589N | Q96RW7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
HMCN1 | SNV | Missense_Mutation | c.16067N>A | p.Gly5356Glu | p.G5356E | Q96RW7 | protein_coding | deleterious(0.02) | probably_damaging(0.922) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HMCN1 | SNV | Missense_Mutation | c.7055A>G | p.Asn2352Ser | p.N2352S | Q96RW7 | protein_coding | tolerated(0.42) | benign(0.033) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |